Sol-Gel Technologies EPS - Earnings per Share 2016-2024 | SLGL
Sol-Gel Technologies eps - earnings per share from 2016 to 2024. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Sol-Gel Technologies Annual EPS |
| 2023 |
$-1.01 |
| 2022 |
$-0.65 |
| 2021 |
$0.14 |
| 2020 |
$-1.30 |
| 2019 |
$-1.26 |
| 2018 |
$-1.80 |
| 2017 |
$-5.02 |
| 2016 |
$-3.30 |
| 2015 |
$-1.53 |
| Sol-Gel Technologies Quarterly EPS |
| 2024-09-30 |
$-0.01 |
| 2024-06-30 |
$0.07 |
| 2024-03-31 |
$-0.23 |
| 2023-12-31 |
$-0.15 |
| 2023-09-30 |
$-0.21 |
| 2023-06-30 |
$-0.22 |
| 2023-03-31 |
$-0.43 |
| 2022-12-31 |
$-0.25 |
| 2022-09-30 |
$-0.15 |
| 2022-06-30 |
$-0.01 |
| 2022-03-31 |
$-0.24 |
| 2021-12-31 |
$0.62 |
| 2021-09-30 |
$0.05 |
| 2021-06-30 |
$-0.35 |
| 2021-03-31 |
$-0.18 |
| 2020-12-31 |
$-0.29 |
| 2020-09-30 |
$-0.37 |
| 2020-06-30 |
$-0.31 |
| 2020-03-31 |
$-0.33 |
| 2019-12-31 |
$-0.33 |
| 2019-09-30 |
$-0.37 |
| 2019-06-30 |
$-0.26 |
| 2019-03-31 |
$-0.30 |
| 2018-12-31 |
$-0.65 |
| 2018-09-30 |
$-0.40 |
| 2018-06-30 |
$-0.36 |
| 2018-03-31 |
$-0.39 |
| 2017-12-31 |
$0.00 |
| 2017-09-30 |
$0.00 |
| 2017-06-30 |
$-0.98 |
| 2016-12-31 |
$0.00 |
| 2015-12-31 |
$0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.012B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
